Status:
COMPLETED
A Retrospective Study of the Effectiveness and Safety of Nivolumab in Advanced/Metastatic Non-Small Cell Lung Cancer (NSCLC) Patients in Japan
Lead Sponsor:
Bristol-Myers Squibb
Collaborating Sponsors:
Ono Pharmaceutical Co. Ltd
Conditions:
Non-Small Cell Lung Cancer
Eligibility:
All Genders
Brief Summary
A Retrospective Study of the Effectiveness and Safety of Nivolumab in Advanced/Metastatic Non-Small Cell Lung Cancer (NSCLC) Patients in Japan
Eligibility Criteria
Inclusion
- Previously treated advanced/metastatic NSCLC patients treated with nivolumab at least once from 01-Apr-2016 through 31-Dec-2016
Exclusion
- Patients who meets the inclusion criteria will be included in the analysis to describe real-world clinical usage of nivolumab. However, patients treated with nivolumab falling in following criteria will be excluded for analysis for the other primary endpoint; overall effectiveness:
- History of participation in any clinical trials prior- or post-nivolumab treatment
- Patients who are a part of a Post-marketing surveillance study
- Other protocol defined inclusion/exclusion criteria could apply
Key Trial Info
Start Date :
April 1 2017
Trial Type :
OBSERVATIONAL
Allocation :
ACTUAL
End Date :
December 31 2018
Estimated Enrollment :
939 Patients enrolled
Trial Details
Trial ID
NCT03273790
Start Date
April 1 2017
End Date
December 31 2018
Last Update
February 3 2022
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Local Institution
Minato-ku, Tokyo, Japan, 1050001